Robert M. Califf

Adjunct Professor of Medicine
Donald F. Fortin, M.D. Distinguished Professor of Cardiology, in the School of Medicine
Member of the Duke Clinical Research Institute
Campus mail 100 Trent Drive, Suite401, Davison Building, Durham, NC 27710
Phone (919) 668-9222
Email address robert.califf@duke.edu

Robert Califf, MD MACC, is the Donald F. Fortin, MD, Professor of Cardiology. He is also Professor of Medicine in the Division of Cardiology and remains a practicing cardiologist. Dr. Califf was the Commissioner of Food and Drugs in 2016-2017 and  Deputy Commissioner for Medical Products and Tobacco from February 2015 until his appointment as Commissioner in February 2016. Prior to joining the FDA, Dr. Califf was a professor of medicine and vice chancellor for clinical and translational research at Duke University. He also served as director of the Duke Translational Medicine Institute and founding director of the Duke Clinical Research Institute. A nationally and internationally recognized expert in cardiovascular medicine, health outcomes research, healthcare quality, and clinical research, Dr. Califf has led many landmark clinical trials and is one of the most frequently cited authors in biomedical science, with more than 1,200 publications in the peer-reviewed literature.

Dr. Califf is a Member of the National Academy of Medicine (formerly known as the Institute of Medicine (IOM)) in 2016, one of the highest honors in the fields of health and medicine. Dr. Califf has served on numerous IOM committees, and he has served as a member of the FDA Cardiorenal Advisory Panel and FDA Science Board's Subcommittee on Science and Technology. Dr. Califf has also served on the Board of Scientific Counselors for the National Library of Medicine, as well as on advisory committees for the National Cancer Institute, the National Heart, Lung, and Blood Institute, the National Institute of Environmental Health Sciences and the Council of the National Institute on Aging.

He has led major initiatives aimed at improving methods and infrastructure for clinical research, including the Clinical Trials Transformation Initiative (CTTI), a public-private partnership co-founded by the FDA and Duke. He also served as the principal investigator for Duke's Clinical and Translational Science Award and the NIH Health Care Systems Research Collaboratory coordinating center and co-PI of the Patient Centered Outcomes Research Institute Network.

Publications

Partin, Melissa R., Aasma Shaukat, David B. Nelson, Amy Gravely, Sean Nugent, Ziad F. Gellad, and James F. Burgess. “Reply.” Clin Gastroenterol Hepatol 14, no. 3 (March 2016): 486. https://doi.org/10.1016/j.cgh.2015.12.008.

PMID
26689898
Full Text

Selker, Harry P., John B. Buse, Robert M. Califf, Robert Carter, Dan M. Cooper, Jonathan Davis, Daniel E. Ford, et al. “CTSA Consortium Consensus Scientific Review Committee (SRC) Working Group Report on the SRC Processes.” Clin Transl Sci 8, no. 6 (December 2015): 623–31. https://doi.org/10.1111/cts.12306.

PMID
26184433
Full Text

Preiss, David, Laine E. Thomas, Daniel M. Wojdyla, Steven M. Haffner, Jason M. R. Gill, Thomas Yates, Melanie J. Davies, et al. “Prospective relationships between body weight and physical activity: an observational analysis from the NAVIGATOR study.” Bmj Open 5, no. 8 (August 14, 2015): e007901. https://doi.org/10.1136/bmjopen-2015-007901.

PMID
26275900
Full Text

Yates, T., M. J. Davies, S. M. Haffner, P. J. Schulte, L. Thomas, K. M. Huffman, C. W. Bales, et al. “Physical activity as a determinant of fasting and 2-h post-challenge glucose: a prospective cohort analysis of the NAVIGATOR trial.” Diabet Med 32, no. 8 (August 2015): 1090–96. https://doi.org/10.1111/dme.12762.

PMID
25818859
Full Text

Kelly, Jacob P., Robert J. Mentz, Vic Hasselblad, Justin A. Ezekowitz, Paul W. Armstrong, Faiez Zannad, G Michael Felker, Robert M. Califf, Christopher M. O’Connor, and Adrian F. Hernandez. “Worsening heart failure during hospitalization for acute heart failure: Insights from the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF).” Am Heart J 170, no. 2 (August 2015): 298–305. https://doi.org/10.1016/j.ahj.2015.04.007.

PMID
26299227
Full Text

Khazanie, Prateeti, Gretchen M. Heizer, Vic Hasselblad, Paul W. Armstrong, Robert M. Califf, Justin Ezekowitz, Kenneth Dickstein, et al. “Predictors of clinical outcomes in acute decompensated heart failure: Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure outcome models.” Am Heart J 170, no. 2 (August 2015): 290–97. https://doi.org/10.1016/j.ahj.2015.04.006.

PMID
26299226
Full Text

Maaten, Jozine M. ter, Allison M. Dunning, Mattia A. E. Valente, Kevin Damman, Justin A. Ezekowitz, Robert M. Califf, Randall C. Starling, et al. “Diuretic response in acute heart failure-an analysis from ASCEND-HF.” Am Heart J 170, no. 2 (August 2015): 313–21. https://doi.org/10.1016/j.ahj.2015.05.003.

PMID
26299229
Full Text

Cannon, Christopher P., Michael A. Blazing, Robert P. Giugliano, Amy McCagg, Jennifer A. White, Pierre Theroux, Harald Darius, et al. “Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.” N Engl J Med 372, no. 25 (June 18, 2015): 2387–97. https://doi.org/10.1056/NEJMoa1410489.

PMID
26039521
Full Text

Washam, Jeffrey B., Susanna R. Stevens, Yuliya Lokhnygina, Jonathan L. Halperin, Günter Breithardt, Daniel E. Singer, Kenneth W. Mahaffey, et al. “Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF).” Lancet 385, no. 9985 (June 13, 2015): 2363–70. https://doi.org/10.1016/S0140-6736(14)61836-5.

PMID
25749644
Full Text

Pages